Levetiracetam

Levetiracetam Market Outlook

The global levetiracetam market is projected to reach approximately USD 2.5 billion by 2035, with a compound annual growth rate (CAGR) of around 7.5% during the forecast period of 2025-2035. This growth can be attributed to the increasing prevalence of epilepsy and seizure disorders, rising awareness about neurological diseases, and advancements in drug formulations. The demand for effective antiepileptic medications is further bolstered by the growing inclination towards personalized medicine, which promotes tailored therapeutic approaches for patients. Additionally, the expansion of healthcare infrastructure and access to medications in emerging economies is poised to contribute significantly to market growth. The integration of advanced technologies in drug development and the rising trend of online pharmacies are also expected to positively influence the levetiracetam market.

Growth Factor of the Market

The growth of the levetiracetam market is primarily driven by the increasing incidence of epilepsy, which is among the most common neurological disorders, affecting millions globally. Furthermore, the rising geriatric population, who are more susceptible to neurological disorders, is adding to the demand for effective treatments. Another significant factor is the enhanced focus on research and development activities aimed at improving the efficacy and safety profile of levetiracetam formulations. The trend towards self-medication and the availability of levetiracetam through various distribution channels, including online pharmacies, have also been pivotal in expanding market reach. Moreover, the successful patent expirations of various levetiracetam formulations have paved the way for generic alternatives, increasing market accessibility and affordability.

Key Highlights of the Market

• The market is anticipated to grow at a CAGR of 7.5% from 2025 to 2035.
• North America is projected to dominate the market due to high healthcare expenditure and robust infrastructure.
• Tablet formulations hold a significant market share, driven by their convenience and efficacy.
• The rising prevalence of epilepsy and related disorders is a key growth driver.
• Online pharmacies are increasingly becoming a popular distribution channel for levetiracetam

By Product Type

Tablets:

Tablets represent the predominant product type within the levetiracetam market, as they are widely preferred due to their ease of administration and accurate dosing. The tablet formulations are available in various strengths, catering to diverse patient needs based on their medical conditions and doctor recommendations. The growing preference for oral administration over other forms of medication delivery stems from the convenience and comfort it offers to patients, especially in the outpatient settings. The market for levetiracetam tablets is expected to continue its expansion, driven by increased awareness about epilepsy and the importance of adhering to prescribed treatment regimens. Additionally, advancements in manufacturing processes that enhance the stability and bioavailability of these formulations contribute to their growing popularity among healthcare professionals and patients alike.

Oral Solution:

The oral solution form of levetiracetam is particularly beneficial for patients who have difficulty swallowing tablets, such as children and the elderly. This product type is gaining traction as it allows for flexible dosing and quick absorption, which is essential in the management of acute seizures. The availability of flavored oral solutions further enhances patient compliance, making it easier for caregivers to administer the medication. As the market evolves, the demand for oral solutions is likely to increase, driven by the need for more inclusive treatment options that cater to diverse patient populations. Healthcare providers are recognizing the importance of patient-centric formulations, which is expected to support the growth of this segment in the coming years.

Injectable Solution:

Injectable solutions of levetiracetam are primarily utilized in hospital settings for acute seizure management and are essential for patients who require immediate intervention. This product type is critical for emergency situations where oral administration is not feasible. The injectable form offers rapid onset of action, making it a vital component of epilepsy treatment protocols in acute care environments. The market for injectable solutions is expected to grow as healthcare providers increasingly adopt standardized protocols for seizure management that emphasize timely and effective treatment. As awareness about epilepsy management escalates among healthcare professionals, the demand for injectable levetiracetam is anticipated to rise, leading to an expansion of this product segment.

Extended-release Tablets:

Extended-release tablets of levetiracetam are designed to provide a controlled release of the active ingredient over an extended period, which leads to improved patient adherence and reduced frequency of dosing. This formulation is especially advantageous for patients requiring consistent therapeutic levels throughout the day. The convenience associated with extended-release formulations makes them a preferred choice for many healthcare providers. With the increasing focus on patient compliance and the importance of maintaining optimal drug levels for effective seizure control, the extended-release segment of the market is projected to witness significant growth. Furthermore, the development of innovative extended-release technologies enhances the market potential for this product type.

Intravenous Solution:

Intravenous solutions of levetiracetam are vital in clinical settings, particularly for patients who are unable to take medications orally. This formulation ensures rapid delivery of the drug directly into the bloodstream, enabling swift action in managing severe seizures. The market for intravenous levetiracetam is driven by the need for effective emergency treatment protocols in hospitals and emergency care settings. As more healthcare providers adopt guidelines that prioritize rapid intervention for seizure management, the demand for intravenous formulations is expected to grow. Additionally, advancements in intravenous administration techniques and equipment will further enhance the feasibility and safety of using this product type in acute care settings.

By Application

Epilepsy:

The application of levetiracetam in epilepsy management is one of its primary uses, as it is widely recognized for its efficacy in controlling various types of seizures. Levetiracetam is particularly effective in treating partial-onset seizures and generalized seizures in adults and children. Its unique mechanism of action, which involves modulating neurotransmitter release, contributes to its effectiveness in managing epilepsy. As the global prevalence of epilepsy continues to rise, driven by factors such as an aging population and increased diagnosis rates, the demand for effective antiepileptic medications like levetiracetam is expected to surge. Additionally, ongoing research into enhancing the drug's profile and exploring its use in combination therapies will further solidify its position in epilepsy treatment.

Seizures:

In addition to treating epilepsy, levetiracetam is used in managing various seizure disorders, which encompass a broader range of neurological conditions. This application is critical as it addresses the immediate needs of patients experiencing seizures not classified strictly under epilepsy. Levetiracetam's versatility in treating diverse seizure types makes it a valuable asset in emergency medicine and outpatient therapy. The market for this application is anticipated to expand as more healthcare professionals recognize the importance of rapid intervention and the role of levetiracetam in acute seizure management. The growing awareness and education surrounding seizure disorders will also contribute to increased utilization of this medication across various healthcare settings.

Anxiety Disorders:

Levetiracetam has gained recognition for its potential application in managing anxiety disorders, which often coexist with epilepsy. Research indicates that the medication may help alleviate anxiety symptoms in patients with a history of seizures, providing a dual benefit for this demographic. The growing acknowledgment of the link between neurological disorders and mental health has opened new avenues for the use of levetiracetam beyond its traditional indications. The demand for effective treatments addressing both anxiety and seizure management is likely to drive market growth in this segment. Furthermore, as mental health awareness continues to rise, the exploration of levetiracetam's off-label use for anxiety disorders may lead to increased prescriptions, supporting overall market dynamics.

Bipolar Disorder:

Levetiracetam is increasingly being studied for its potential role in managing bipolar disorder, particularly in patients with comorbid epilepsy or seizure disorders. Its unique pharmacological profile may offer benefits in stabilizing mood and preventing mood swings, making it a consideration in the treatment landscape. The growing understanding of the interplay between neurological and psychiatric conditions has paved the way for broader applications of antiepileptic drugs. The market for this application is poised for growth as healthcare providers seek comprehensive treatment approaches for patients experiencing both neurological and mood-related challenges. Continued research and clinical trials exploring levetiracetam's efficacy in bipolar disorder could further establish its role in psychiatric management.

Migraine Prevention:

Recent studies have indicated that levetiracetam may exhibit efficacy in migraine prevention, particularly in individuals who also suffer from seizure disorders. This application is gaining traction as healthcare providers explore alternative treatment options for migraine patients, particularly those who are intolerant to traditional migraine medications. The potential for levetiracetam to serve dual purposes in managing both migraines and seizures presents an appealing option for patients and clinicians alike. As awareness of levetiracetam's benefits for migraine prevention grows, this application is expected to contribute positively to market dynamics. The ongoing research into the drug's mechanisms and effectiveness in migraine management will further bolster its position in this segment.

By Distribution Channel

Hospitals:

Hospitals are a critical distribution channel for levetiracetam, as they serve as the primary setting for acute seizure management and neurological care. The demand for levetiracetam in hospitals is driven by the necessity for immediate and effective treatment of seizure emergencies. With a focus on patient safety and expedited care, hospitals ensure that levetiracetam is readily available for administration in various formulations, including IV and oral solutions. The market for levetiracetam through hospital distribution is expected to grow in tandem with the increasing number of hospital admissions for seizure-related conditions and the establishment of standardized treatment protocols. As hospitals continue to enhance their neurological care capabilities, this distribution channel will remain a cornerstone of the levetiracetam market.

Retail Pharmacies:

Retail pharmacies play a significant role in the distribution of levetiracetam, particularly for patients managing chronic conditions such as epilepsy. The accessibility of levetiracetam through retail pharmacies ensures that patients can obtain their medication conveniently, promoting adherence to prescribed treatment regimens. With the rising prevalence of epilepsy and an increasing number of patients seeking long-term management options, retail pharmacies are expected to witness growth in the sale of levetiracetam. Additionally, the integration of patient education services within pharmacy settings further enhances the value of retail pharmacies as distribution channels, as pharmacists provide vital information regarding medication usage and side effects, fostering an informed patient base.

Online Pharmacies:

Online pharmacies have emerged as a rapidly growing distribution channel for levetiracetam, driven by the increasing trend of e-commerce in the pharmaceutical sector. The convenience of ordering medications from the comfort of one’s home, along with the ability to compare prices and access a wider selection of products, has made online pharmacies an attractive option for many patients. The COVID-19 pandemic has further accelerated this trend, as patients sought safer alternatives to traditional pharmacy visits. As online pharmacies continue to gain traction, their contribution to the overall levetiracetam market is expected to increase substantially. The enhanced focus on digital health and telemedicine will likely complement this growth, making online pharmacies a vital component of the levetiracetam distribution landscape.

Drug Stores:

Drug stores serve as a traditional distribution channel for levetiracetam, providing essential access to medications for patients. These establishments typically offer a range of healthcare products and are frequented by individuals seeking prescription medications and over-the-counter options. The role of drug stores in the levetiracetam market remains significant, particularly in regions where community pharmacies may be limited. As the demand for levetiracetam continues to rise due to increasing diagnoses of epilepsy and related conditions, drug stores are expected to play a crucial role in ensuring that patients have access to this important medication. The presence of knowledgeable staff who can assist patients in understanding their treatment options further enhances the value of drug stores within this distribution channel.

Clinics:

Clinics, particularly those specializing in neurology and mental health, are increasingly becoming important distribution channels for levetiracetam. These facilities provide comprehensive care for patients with seizure disorders, including ongoing management and medication refills. The direct relationship between healthcare providers and patients within clinic settings fosters individualized treatment plans, leading to enhanced patient adherence to prescribed levetiracetam regimens. As clinics continue to expand their offerings and patient populations grow, the market for levetiracetam within this channel is expected to flourish. Furthermore, the emphasis on patient education and support within clinical environments will further bolster the utilization of levetiracetam for appropriate indications.

By Ingredient Type

Generic:

The generic segment of the levetiracetam market has gained traction following the expiration of patents for branded formulations. Generic versions of levetiracetam offer significant cost savings for patients and healthcare systems, making antiepileptic treatment more accessible and affordable. The availability of multiple manufacturers producing generic levetiracetam has increased competition, leading to lower prices and improved options for patients. The market for generic levetiracetam is expected to grow steadily, driven by the increasing prevalence of epilepsy and the rising demand for cost-effective healthcare solutions. Additionally, healthcare providers are increasingly recommending generics due to their proven efficacy and safety profiles, further supporting market expansion.

Brand:

The brand segment of the levetiracetam market remains significant, particularly for patients seeking specific formulations with established efficacy. Branded products often benefit from strong manufacturer support, including patient education initiatives and extensive marketing efforts aimed at healthcare professionals. Patients may choose brand-name levetiracetam due to familiarity with the product or specific insurance coverage policies favoring branded medications. While the generics market continues to grow, branded levetiracetam will still hold a substantial share of the market, especially in regions where brand loyalty and patient-provider relationships are strong. Manufacturers are likely to continue investing in research and development to innovate and differentiate their branded formulations, thereby maintaining relevance in a competitive landscape.

By Region

The levetiracetam market exhibits significant regional variations, largely influenced by healthcare infrastructure, prevalence of epilepsy, and access to medications. North America holds the dominant share of the market, accounting for approximately 40% of the total revenue in 2025. Factors contributing to this prominence include high healthcare expenditure, advanced medical facilities, and robust regulatory frameworks supporting drug approvals. The region is projected to witness a CAGR of around 7.2% over the forecast period, driven by increased awareness and improved diagnosis rates of epilepsy. Additionally, the presence of established pharmaceutical companies and ongoing research to enhance treatment options will further solidify North America's leadership position in the levetiracetam market.

Europe follows closely behind, capturing approximately 30% of the global market share. The region benefits from a well-established healthcare system and a growing emphasis on neurological disorder management. The increasing prevalence of epilepsy in European countries combined with favorable reimbursement policies is anticipated to drive market growth. The Asia Pacific region is rapidly emerging, with a projected CAGR of 8.5% as healthcare access improves and awareness about seizure disorders increases. Countries such as India and China are witnessing rising demand for effective antiepileptic medications due to their large populations and growing healthcare infrastructure. The Latin America and Middle East & Africa regions are expected to experience moderate growth as access to medications expands and healthcare systems evolve.

Opportunities

The levetiracetam market presents numerous opportunities, particularly with the increasing incidence of epilepsy and seizure-related disorders. As awareness about neurological conditions rises, there is a growing demand for effective treatments that can significantly improve patient quality of life. This presents an opportunity for pharmaceutical companies to invest in research and development to innovate new formulations and delivery methods for levetiracetam. Furthermore, the acceptance of telemedicine and digital healthcare solutions allows for remote patient monitoring and consultations, which could greatly enhance patient adherence to treatment regimens. Companies that leverage technology to provide better patient engagement and education will likely gain a competitive edge in the market.

Another promising opportunity lies in expanding market access to emerging economies, where the burden of epilepsy is substantial yet often underdiagnosed and undertreated. Strategic partnerships with local distributors and healthcare providers can facilitate the introduction of levetiracetam in these markets, ensuring that patients receive the necessary medications. Additionally, educational initiatives aimed at healthcare professionals and patients can further drive awareness about the importance of epilepsy management and the role of levetiracetam. This multi-faceted approach can unlock significant potential for market growth and improve health outcomes for patients in regions with limited access to effective treatments.

Threats

While the levetiracetam market presents numerous opportunities, it also faces several threats that could impact growth. One of the primary threats is the increasing competition from generic formulations, which may drive down prices and reduce the profitability of branded products. As more manufacturers enter the market with generic alternatives, the price pressure may affect the revenue streams of established pharmaceutical companies. Additionally, the possibility of regulatory changes and stringent guidelines around the approval and marketing of antiepileptic medications could hinder market growth. Companies must remain vigilant regarding compliance to avoid potential delays or penalties associated with non-adherence to regulations.

Another significant threat involves the potential side effects and adverse reactions associated with levetiracetam. While generally considered safe, some patients may experience adverse reactions that could lead to discontinuation of therapy. This poses a challenge for healthcare providers in managing patient outcomes and may affect the overall perception of levetiracetam as a treatment option. Furthermore, ongoing research into alternative treatments and therapies for epilepsy may divert attention and resources away from traditional medications like levetiracetam. As the treatment landscape evolves, companies must stay proactive in addressing these challenges to maintain their positions in the market.

Competitor Outlook

• UCB Pharma
• Teva Pharmaceutical Industries
• Mylan N.V.
• Sun Pharmaceutical Industries Ltd.
• Hikma Pharmaceuticals
• Dr. Reddy's Laboratories Ltd.
• Amgen Inc.
• Novartis AG
• Pfizer Inc.
• Sanofi S.A.
• AbbVie Inc.
• Boehringer Ingelheim International GmbH
• Roche Holding AG
• Merck & Co., Inc.
• Johnson & Johnson

The competitive landscape of the levetiracetam market is characterized by the presence of several key players, each striving to capture market share through various strategies such as innovation, partnerships, and product differentiation. UCB Pharma remains a leading competitor, with a strong portfolio of antiepileptic drugs and a commitment to ongoing research in epilepsy treatment. The company's established reputation and extensive market experience position it well to capitalize on growth opportunities within the levetiracetam market. Additionally, UCB's focus on patient-centric approaches and digital health solutions enhances its competitive edge.

Teva Pharmaceutical Industries and Mylan N.V. are also prominent players in the levetiracetam market, particularly in the generic segment. Both companies have robust manufacturing capabilities and extensive distribution networks, allowing them to offer affordable alternatives to branded levetiracetam products. Their competitive pricing strategies and commitment to quality have enabled them to gain significant market share in various regions. Furthermore, these companies are actively engaged in research and development to maintain their leadership positions in the rapidly evolving generic pharmaceutical market.

Sun Pharmaceutical Industries Ltd. and Hikma Pharmaceuticals are other noteworthy competitors, recognized for their innovative approaches to drug formulation and delivery. Sun Pharma's focus on expanding its neurological product offerings, coupled with Hikma's strategic partnerships for market access, positions both companies favorably in the levetiracetam market. Their commitment to quality and patient safety enhances their reputation and strengthens their market presence. As the competitive landscape continues to evolve, these companies, along with others, will need to adapt their strategies to respond to emerging trends and patient needs.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Amgen Inc.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Mylan N.V.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 UCB Pharma
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 AbbVie Inc.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Novartis AG
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Pfizer Inc.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Sanofi S.A.
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Roche Holding AG
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Johnson & Johnson
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Merck & Co., Inc.
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Hikma Pharmaceuticals
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Dr. Reddy's Laboratories Ltd.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Teva Pharmaceutical Industries
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Sun Pharmaceutical Industries Ltd.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Boehringer Ingelheim International GmbH
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Levetiracetam Market, By Application
    • 6.1.1 Epilepsy
    • 6.1.2 Seizures
    • 6.1.3 Anxiety Disorders
    • 6.1.4 Bipolar Disorder
    • 6.1.5 Migraine Prevention
  • 6.2 Levetiracetam Market, By Product Type
    • 6.2.1 Tablets
    • 6.2.2 Oral Solution
    • 6.2.3 Injectable Solution
    • 6.2.4 Extended-release Tablets
    • 6.2.5 Intravenous Solution
  • 6.3 Levetiracetam Market, By Ingredient Type
    • 6.3.1 Generic
    • 6.3.2 Brand
  • 6.4 Levetiracetam Market, By Distribution Channel
    • 6.4.1 Hospitals
    • 6.4.2 Retail Pharmacies
    • 6.4.3 Online Pharmacies
    • 6.4.4 Drug Stores
    • 6.4.5 Clinics

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Levetiracetam Market by Region
  • 10.4 Latin America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 Brazil
      • 10.4.1.2 Argentina
      • 10.4.1.3 Mexico
  • 10.5 North America - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 USA
      • 10.5.1.2 Canada
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Levetiracetam market is categorized based on

By Product Type

• Tablets
• Oral Solution
• Injectable Solution
• Extended-release Tablets
• Intravenous Solution

By Application

• Epilepsy
• Seizures
• Anxiety Disorders
• Bipolar Disorder
• Migraine Prevention

By Distribution Channel

• Hospitals
• Retail Pharmacies
• Online Pharmacies
• Drug Stores
• Clinics

By Ingredient Type

• Generic
• Brand

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• UCB Pharma
• Teva Pharmaceutical Industries
• Mylan N.V.
• Sun Pharmaceutical Industries Ltd.
• Hikma Pharmaceuticals
• Dr. Reddy's Laboratories Ltd.
• Amgen Inc.
• Novartis AG
• Pfizer Inc.
• Sanofi S.A.
• AbbVie Inc.
• Boehringer Ingelheim International GmbH
• Roche Holding AG
• Merck & Co., Inc.
• Johnson & Johnson